American Century Companies Inc. Purchases 521,683 Shares of SiBone $SIBN

American Century Companies Inc. increased its holdings in SiBone (NASDAQ:SIBN) by 22.5% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,838,107 shares of the company’s stock after buying an additional 521,683 shares during the period. American Century Companies Inc. owned 0.07% of SiBone worth $41,777,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in SiBone by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock worth $343,000 after buying an additional 1,053 shares in the last quarter. State of Alaska Department of Revenue purchased a new stake in shares of SiBone in the 3rd quarter valued at about $39,000. State of Wyoming purchased a new stake in shares of SiBone in the 2nd quarter valued at about $55,000. Tower Research Capital LLC TRC boosted its position in shares of SiBone by 198.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,897 shares of the company’s stock valued at $92,000 after acquiring an additional 3,258 shares during the last quarter. Finally, Canada Pension Plan Investment Board purchased a new position in shares of SiBone during the second quarter worth about $68,000. Institutional investors own 98.11% of the company’s stock.

Analysts Set New Price Targets

SIBN has been the topic of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of SiBone in a research report on Monday, December 29th. TD Cowen boosted their target price on SiBone from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Tuesday, February 24th. Needham & Company LLC upped their target price on SiBone from $24.00 to $27.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. Truist Financial reissued a “buy” rating and issued a $24.00 target price (up from $23.00) on shares of SiBone in a research note on Tuesday, February 24th. Finally, Morgan Stanley increased their target price on SiBone from $20.00 to $23.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, SiBone has a consensus rating of “Moderate Buy” and a consensus price target of $24.67.

SiBone Trading Down 1.7%

SIBN opened at $13.83 on Friday. The stock has a market cap of $610.87 million, a PE ratio of -31.43 and a beta of 0.69. The company has a quick ratio of 7.21, a current ratio of 8.55 and a debt-to-equity ratio of 0.20. The business has a 50 day moving average of $16.88 and a 200-day moving average of $16.80. SiBone has a 52 week low of $12.49 and a 52 week high of $21.89.

SiBone (NASDAQ:SIBN) last posted its quarterly earnings results on Monday, February 23rd. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.09. SiBone had a negative return on equity of 11.01% and a negative net margin of 9.41%.The firm had revenue of $56.35 million during the quarter, compared to analyst estimates of $56.26 million. Equities research analysts predict that SiBone will post -0.78 earnings per share for the current fiscal year.

Insider Transactions at SiBone

In other SiBone news, SVP Michael A. Pisetsky sold 20,756 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $15.35, for a total transaction of $318,604.60. Following the sale, the senior vice president directly owned 285,974 shares of the company’s stock, valued at $4,389,700.90. This trade represents a 6.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey W. Dunn sold 20,000 shares of SiBone stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $21.28, for a total transaction of $425,600.00. Following the completion of the sale, the director owned 80,115 shares in the company, valued at approximately $1,704,847.20. This represents a 19.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 247,653 shares of company stock valued at $4,234,702. Company insiders own 4.00% of the company’s stock.

SiBone Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.